Navigation Links
Potential treatment for deadly E. coli disease
Date:6/7/2011

A potential life-saving treatment for severe E. coli food poisoning outbreaks developed more than a decade ago hasn't gone forward into clinical trials because of lack of commercial interest.

University of Adelaide researchers produced a "designer" probiotic bacterium which binds and neutralises the toxin produced by E. coli, which causes life-threatening attack on the kidneys and blood vessels.

The team of scientists Dr Adrienne Paton, Associate Professor Renato Morona and Professor James Paton showed that mice infected with a highly virulent strain of E. coli were completely protected by the probiotic bacterium.

The research was published in the prestigious journal Nature Medicine in 2000 and generated ongoing interest from the scientific and medical community but the commercial sector hasn't taken up its development for progress into clinical trials in humans.

"Severe E. coli food poisoning outbreaks such as that currently occurring in Europe are becoming increasingly common," said Professor Paton, Director, Research Centre for Infectious Diseases at the University of Adelaide.

"They have the potential to cause widespread disease and many patients develop life-threatening complications including kidney failure.

"The probiotic bacterium could be produced cheaply on a large scale. However, in spite of on-going attention from the scientific and medical community, there has been a lack of interest from the commercial sector in taking this product forward into clinical trials.

"If this had been done, and the probiotic had been proven to be safe and efficacious in humans, it could have been deployed during the current European outbreak. This would undoubtedly have saved lives, as well as millions of dollars in current and future health care costs."

The researchers engineered a harmless bacterium to mimic binding receptors for the potentially fatal Shiga toxin on its surface.

Professor Paton said after diagnosis of E. coli infection there was a window of opportunity for therapeutic intervention before kidneys started to fail. Antibiotics are not used because they can increase the amount of toxin released in the gut.


'/>"/>

Contact: Professor James Paton
james.paton@adelaide.edu.au
61-414-732-967
University of Adelaide
Source:Eurekalert

Related biology news :

1. Estimating landfill gas potential
2. CDC assesses potential human exposure to prion diseases
3. Scientists find new class of compounds with great potential for research and drug development
4. Liquid smoke from rice shows potential health benefits
5. CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research
6. Discovery demonstrates potential MS therapy could kill brain cells
7. GW researchers reveal 18 novel subtype-dependent genetic variants for autism spectrum disorders and identify potential genetic markers for diagnostic screening
8. Satellite tracking of sea turtles reveals potential threat posed by manmade chemicals
9. Viral replicase points to potential cancer therapy
10. School energy audits find millions in potential energy savings
11. A diabetes drug, sitagliptin, also has a potential to prevent diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology: